A young Peninsula drug developer with less than $5 million in hand will wind down its operations after its attempt at a reverse triangular merger fell apart. Vincerx Pharma Inc. (Nasdaq ...

The contemplated transaction would result in QumulusAI becoming a publicly traded company through a reverse triangular merger with Vincerx. A subsidiary of Vincerx would merge into QumulusAI ...

This will be followed by a reverse triangular merger, in which a wholly owned SB6 subsidiary, Summit Bright LLC, will merge into Ampere. The merger will result in Ampere becoming an indirect ...

Previously, Vincerx had revealed plans for a reverse triangular merger with QumulusAI, which would have made QumulusAI a publicly traded entity. In another development, Vincerx Pharma and Oqory ...